Abstract: The present invention is directed to novel cyclopropanated macrocyclic ketone and lactone compounds of the general formula wherein X is an atom or a functional group selected from the group consisting of O, N, S, CH, or CH2; wherein Y is a straight or branched hydrocarbon moiety consisting of 1 to 20 carbon atoms; wherein W is a straight or branched hydrocarbon moiety of consisting of 1 to 20 carbon atoms; and wherein O is an oxygen atom; and the use of these novel compounds in creating fragrances, and scents in items such as perfumes, colognes and personal care products.

Abstract: The present invention is directed to novel cyclopropanated macrocyclic ketone and lactone compounds of the general formula wherein X is an atom or a functional group selected from the group consisting of O, N, S, R—CH, CH2 and wherein R is a C1-C3 alkyl group; a wherein Y and W independently represent is a linear or branched alkyl or alkenyl group, possibly substituted, consisting of less than 10 and preferably less than 7 carbon atoms; and wherein O is an oxygen atom; and the use of these novel compounds in creating fragrances, and scents in items such as perfumes, colognes and personal care products.

Abstract: A method for for repelling arthropods involving treating an object or area with an arthropod repelling effective amount of at least one isolongifolenone analog (and optionally a carrier or carrier material).

Abstract: The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E 1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ?380, preferably of ?600, most preferably ?900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ?30% when pressed to tablets.

Abstract: Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately.

Abstract: An object of the invention is to provide a gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester. Abnormal gene expression due to, for example, oxidative stress can be treated, improved, and/or prevented, and diseases caused by the abnormal gene expression can be treated, improved, and/or prevented. A gene expression regulating agent which includes astaxanthin and/or its ester as an effective ingredient; and a food and drink having an effect of regulating gene expression which includes astaxanthin and/or its ester are provided and are useful for treating, improving, and/or preventing the symptom caused by the abnormal gene expression, that is, excessive expression or suppression of expression.

Abstract: The invention pertains to a water dispersible, preferably a powder composition of water extractible bioactive components of exclusively fruit or vegetable or plant origin. These components are obtainable by: a) subjecting a selected fruit or vegetable or plant material to homogenisation in weak alkaline conditions and at moderate temperature; b) separating the liquid extract from the homogenised mass and subsequently bringing it to neutrality; and c) eventually concentrating or drying, preferably by freeze drying, the neutralized liquid extract. The composition can be used as primary composition in the preparation of a food product for oral administration, a food supplement, a pet food product, a pet food supplement, a cosmetic preparation or a pharmaceutical preparation.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed.

Abstract: Compositions in fine powder form that can be obtained by means of a dry co-grinding process of an at least ternary mixture consisting of an active substance, a carrier and at least one auxiliary co-grinding substance, wherein the active substance is constituted by one or more micronutrient substances with particular antioxidant activity. Such compositions have shown a significant increase in active substance antioxidant power in comparison to solutions of equal active substance content. Said effect is particularly useful for uses for active substances included in antioxidant compositions in the pharmaceutical, cosmetic and dietary-nutritional fields.

Abstract: This invention comprises antineoplastic curcumin derivatives and methods of preparation and use thereof. Particular reference is made to the following isomeric compounds wherein R1, R2, and R3 are selected from the group consisting of H, OH, OCH3, and COOH.

Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.

Abstract: Novel, safe, and highly effective agents for increasing adiponectin in blood that contain astaxanthin and/or an ester thereof as an active component are provided. Due to an increase in the amount of adiponectin in blood, the action of adipocytokine such as TNF? can be decreased, or the action of biologically active substances such as insulin can be protected from the adverse action of adipocytokine. It is expected that, as a result, insulin resistance and hyperinsulinemia caused by adipocytokine, and metabolic syndrome are prevented or suppressed. Furthermore, it is expected that progress of arteriosclerosis, which can lead to cardiovascular diseases and cerebrovascular diseases, is inhibited by ingestion of the agent for increasing adiponectin in blood of the present invention, because arteriosclerosis progresses due to a decrease in adiponectin.

Abstract: Compositions and methods for controlling an arthropod pest population that include an eremophilane sesquiterpene pest control agent (such as, nootkatone or 13-hydroxy-valencene) and a dialkyl-substituted phenol pest control agent (such as, carvacrol) are disclosed. The compounds present in the compositions may be isolated from natural sources, semi-synthesized from naturally occurring compounds, or completely synthesized. The pest control compositions may be applied directly to a pest or the locus of a pest, and function as topical or ingestible pest toxins.

Abstract: The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.

Abstract: Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula wherein R1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R2, R3, and R4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R5 is hydrogen, CH3, or CH2OH, and R6 is an organo group such as a hydrocarbon having from 1 to 10 carbon atoms are disclosed. Other seco-pseudopterosins and compounds related to pseudopterosins are disclosed.

Abstract: The present invention provides a circadian rhythm normalizing composition containing astaxanthin and/or its ester as an active ingredient, and a composition having the action of enhancing the circadian rhythm normalizing action of melatonin by protecting melatonin. The composition can be in the form of a drug, a functional food, a food or a beverage. This composition has a circadian rhythm normalizing action, and has the action of preventing or alleviating sleep disorder and various diseases due to disturbance of the circadian rhythm.

Abstract: A method and composition is provided for organ rescue wherein a specific counter-measure is applied locally to a tissue at risk for or exhibiting an adverse side effect of a cancer treatment. More particularly, the method and composition is directed at controlling Hand-Foot Syndrome, a painful redness and cracking of the skin of the hands and feet which can occur with systemic treatment with 5-fluorouracil or a precursor thereof. Uracil ointment is applied to the skin of the hands and feet to prevent Hand-Foot Syndrome which can occur from systemic administration of 5-fluorouracil (or precursor thereof) as cancer treatment.

Abstract: The present invention provides compounds of general formula I or II: wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I or II, intermediates and processes useful for preparing compounds of formula I or II, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I or II.

Abstract: Extracts of vetiver oil were found to be significant repellents and toxicants of ants, ticks, and cockroaches. Nootkatone was shown to significantly decrease ant invasion and increase mortality in fire ants. Nootkatone is an effective repellent and toxicant of ants either by itself or as an addition to other substrates, including mulches made from vetiver grass roots, diatomaceous earth, alumina, silica, clays; building materials made from either aluminum or wood; and other suitable solid substances. Nootkatone was also a repellent and toxicant to ticks; and a repellent to cockroaches. Nootkatone is non-toxic to humans and other mammals and is environmentally safe. In addition, it is believed that other extracts of vetiver oil, specifically ?-cedrene, zizanol and bicyclovetivenol, will be effective against ants, ticks, and cockroaches.

Abstract: Two derivatives of nootkatone, tetrahydronootkatone and 1,10-dihydronootkatone, are surprisingly effective as repellents of termites and mosquitos. Tetrahydronootkatone and 1,10-dihydronootkatone were shown to effectively repel termites at concentrations as low as 2 ?g/ml and 12.5 ?g/ml, respectively. Tetrahydronootkatone was shown to repel mosquitos at a concentration of 5%. Tetrahydronootkatone is an effective repellent of termites either by itself or as an addition to other substrates, including mulches made from wood products or other cellulose-containing material. Tetrahydronootkatone or 1,10-dihydronootkatone can be used to protect construction wood from attack by Formosan subterranean termites, either alone or used in combination with other compounds known to repel termites. It is also believed that these compounds will prove effective in repelling ants, ticks, and cockroaches. These derivatives of nootkatone are non-toxic to humans and other mammals and environmentally safe.

Abstract: Extracts of vetiver oil were found to significantly repel termites. In one extract, nootkatone was isolated and found to be a significant repellent and toxicant of termites. Nootkatone significantly decreased food consumption, decreased tunneling behavior, and increased mortality in termites. Nootkatone is an effective repellent and toxicant of termites either by itself or as an addition to other materials or substrates, including mulches made from vetiver grass roots or other wood products. Nootkatone can also be used to protect construction wood from attack by Formosan subterranean termites. Nootkatone as a repellent is non-toxic to humans and other mammals and is environmentally safe. In addition, ?-cedrene was found to be a weak termite repellent; and both zizanol and bicyclovetivenol were found to be repellents and toxicants of termites.

Abstract: The present invention provides illudin analogs of the general formula I: wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I, intermediates and processes useful for preparing compounds of formula I, and methods comprising inhibiting tumor growth or treating cancer by administering one or more compounds of formula I.

Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.

Abstract: Mosquito-repellant and insecticidal compounds identified as oils present in the plant Blumea lacera [Burm. F.] DC. These compounds may be extracted from a plant source or synthetically synthesized and formulated to make anti-mosquito products.

Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.

Abstract: Extracts of vetiver oil were found to be significant repellents and toxicants of ants, ticks, and cockroaches. Nootkatone was shown to significantly decrease ant invasion and increase mortality in fire ants. Nootkatone is an effective repellent and toxicant of ants either by itself or as an addition to other substrates, including mulches made from vetiver grass roots, diatomaceous earth, alumina, silica, clays; building materials made from either aluminum or wood; and other suitable solid substances. Nootkatone was also a repellent and toxicant to ticks; and a repellent to cockroaches. Nootkatone is non-toxic to humans and other mammals and is environmentally safe. In addition, it is believed that other extracts of vetiver oil, specifically &agr;-cedrene, zizanol and bicyclovetivenol, will be effective against ants, ticks, and cockroaches.

Abstract: The activity of the enzyme aromatase is inhibited by administering an aromatase inhibiting amount of a composition comprising at least one of astaxanthin, black cohosh, echinacea, and phytosterols to a subject.

Abstract: The present invention relates to a prolactin lowering drug containing at least one bicyclic diterpene of the labdane type.

Abstract: A potassium channel opener comprising a compound (e.g.

Abstract: Methods of treating a bacterial infection and of killing or inhibiting bacteria are disclosed. The methods use derivatives of triterpenes that are abundant in birch bark and other plants. The triterpenes include betulin, allobetulin, and lupeol.

Abstract: The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.

Abstract: Compounds, compositions, and methods for controlling an arthropod pest population that employ an eremophilane sesquiterpene parent structure are presented. The compounds have minimal adverse or toxic effects on humans, non-human animals, and the natural environment. The compounds may be isolated from natural sources, semi-synthesized from naturally occurring compounds, or completely synthesized. The compounds may be applied directly to a pest, or the locus of a pest, and function as topical or ingestible toxins. Eremophilane sesquiterpenes 13-hydroxy-valencene, valencene-11,12-epoxide, valencene-13-aldehyde, and nootkatone-1,10-11,12-diepoxide are exemplary compounds.

Abstract: A wasp controlling liquid formulation, which comprises a pesticidal compound as an active ingredient and at least 30% by weight of a saturated hydrocarbon that has a boiling point from 90° C. to 200° C., provides superior potency and an ability to knock down or kill wasps before the wasp has a chance to formidably sting someone.

Abstract: 1-Deoxybaccatin III, 1-deoxytaxol and 1-deoxy taxol analogs and method for the preparation thereof.

Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.

Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1.

Abstract: The present invention relates to a prolactin lowering drug containing at least one bicyclic diterpene of the labdane or clerodane type: wherein R1=H, C1 to C3 alkyl or C1 to C3 acyl.

Abstract: The invention includes a method of treating neurogenic urinary dysfunction that comprises contacting urinary bladder mucosa of a patient afflicted with neurogenic urinary dysfunction with an effective dose of a homovanilloid compound, in particular a compound selected from the group RTX, TYX, 20-homovanillyl-mezerein or 20-homovanillyl-12-deoxyphorbol-13-phenylacetate. The invention includes treatment of urge incontinence due to detrusor hyperreflexia (DH). The invention also includes treatment of sensory hypersensitivity of the bladder resulting from prostate hypertrophy or interstial cystitis, as well as other neurogenic conditions resulting in increased micturition frequency or decreased bladder capacity, with or without frank incontinence.

Abstract: A &ohgr;-cycloalkyl-prostaglandin E2 derivatives of the formula (I) 1

Abstract: A water soluble derivative of buckministerfullerene (C60) having antiviral and virucidal properties is used to inhibit human retroviral replication and infections. The derivatized fullerene is symmetrically substituted with polar organic moieties containing 1 to 20 carbon atoms and optionally further containing oxygen or nitrogen.

Abstract: Preparations are disclosed containing the 3R-3′R stereoisomer of zeaxanthin, packaged for oral ingestion by humans as a therapeutic drug or nutritional supplement. Zeaxanthin is a yellow carotenoid pigment found in the macula (in the center of the human retina), which helps protect retinal cells against phototoxic damage. The R-R stereoisomer can be prepared by fermenting cells, such as Flavobacterium multivorum (ATCC 55238), which do not create any detectable quantity of the undesired and potentially toxic S-S or S-R isomers, and which do not synthesize any other carotenoids. The R-R isomer can be concentrated, in large quantities and at low cost, into a viscous oily fluid containing about 5 to 20% zeaxanthin, by means of a simple solvent extraction process. This oily fluid can be mixed with a carrier such as vegetable oil and enclosed within a digestible capsule, comparable to a conventional capsule containing Vitamin E.

Abstract: The present invention related to an oligocycloalkanoid compound comprising formula (I) wherein m, n, and o are independently an integer from 0 to 2; A1 through A10 are independently a direct link, alkylene, alkylene-O—, carbonyl, oxygen, or sulfur; X and Y are independently hydrogen, hydroxy, alkyl, or in combination an electrophilic group; and R1 through R10 are independently hydrogen, hydroxy, alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, N-, S-, or O-heterocycles, fused or multi-ring aryl with or without hetero ring members, arylalkyl, arylalkenyl, arylalkynyl, alkylphenyl, alkenylphenyl, alkynylphenyl, alkoxy, alkenyloxy, alkynyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted arylalkoxy, alkylacyl, alkenylacyl, alkynylacyl, arylacyl, aroyl, alkylaroyl, aminoaroyl, aminoalkylacyl, aminoalkyl, aminoalkenyl, aminoalkynyl, amino, alkylamino, alkenylamino, alkynylamino, arylamino, dialkylamino, dialkenylamino, dialkynylamino, arylalkylamino, arylalk

Abstract: Newly-isolated and purified metabolites which are effective in regulating the development of at least one filamentous fungal microorganism species are disclosed. These compounds, which are referred to as conidiogenol and conidiogenone, may be used to induce conidiation in and/or to inhibit the growth of populations of such fungal species. The compounds are preferably produced by culture of the fungal species Penicillium cyclopium, and may be subsequently recovered from the culture medium and purified. Methods of using and methods of producing these compounds are also disclosed.

Abstract: Administration of a pharmaceutical composition in the form of a suppository comprising: (a) a prostaglandin vasodilator; (b) 15-hydroxyprostaglandindehydrogenase inhibitor: and (c) a base material that is solid at room temperature and releases components (a) and (b) when inserted in the urethra, is effective for the treatment of male erectile dysfunction.

Abstract: A method of inhibiting the expression of inflammatory cytokines and chemokines in an animal or man, is disclosed. The method comprises administration to said animal or man of at least one type of xanthophyll, e.g. astaxanthin, in an amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man. Use of at least one type of xanthophyll, such as astaxanthin, for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines in an animal or man, is described. Further, a commercial package containing a medicament comprising at least one type of xanthophyll, e.g. astaxanthin, and written and/or data carrier instructions for administration to an animal or man of the medicament for the prophylactic and/or therapeutic inhibition of the express of inflammatory cytokines and chemokines, is disclosed.

Abstract: Extracts of vetiver oil were found to be significant repellents and toxicants of ants, ticks, and cockroaches. Nootkatone was shown to significantly decrease ant invasion and increase mortality in fire ants. Nootkatone is an effective repellent and toxicant of ants either by itself or as an addition to other substrates, including mulches made from vetiver grass roots, diatomaceous earth, alumina, silica, clays; building materials made from either aluminum or wood; and other suitable solid substances. Nootkatone was also a repellent and toxicant to ticks; and a repellent to cockroaches. Nootkatone is non-toxic to humans and other mammals and is environmentally safe. In addition, it is believed that other extracts of vetiver oil, specifically &agr;-cedrene, zizanol and bicyclovetivenol, will be effective against ants, ticks, and cockroaches.

Abstract: Novel compounds are disclosed that have the following chemical structures, and prodrug esters and acid-addition salts thereof, that are useful as Interleukin-1 and Tumor Necrosis Factor-&agr; modulators, and thus are useful in the treatment of various diseases.

Abstract: An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1.

Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.

Abstract: A compound of formula (I): 1